GXO Logistics Inc vs Zoetis Inc — how do they compare? GXO Logistics Inc trades at $46.56 (market cap $5.32B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 5.7× GXO Logistics Inc's market cap, and Zoetis Inc pays a 2.9% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and Zoetis Inc for 70 Days on average.
| GXO | ZTS | |
|---|---|---|
Market Cap | $5.32B | $30.20B |
Volume | 1,255,816 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $65.59 | $147.53 |
52-Week Low | $44.17 | $69.09 |
Typical Hold Time | 28 Days | 70 Days |
Enterprise Value | $10.67B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
GXO trades at $46.56, up 1.24% today, with a neutral technical signal and bearish moving average trend. The company reported Q2 2026 EPS of $0.59, beating estimates, and maintains strong analyst support with an 88.89% buy rating. Recent news highlights strategic partnerships with Columbia Sportswear and expansion in aerospace & defense, signaling growth initiatives. Revenue for 2025 was $13.18 billion, with a net income margin of 0.96%, though profitability remains modest.
The outlook is positive, driven by analyst consensus price target of $66.67 and improving industry prospects. Key opportunities include operational efficiency gains from new labor management systems and sector tailwinds. Risks involve stagnant margins and competitive pressures, requiring close monitoring of execution on growth targets to justify current valuations.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Trailing returns across standard periods
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →